Cargando…

Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study

Relapsing-remitting multiple sclerosis (RRMS) is a degenerative, inflammatory disease of the central nervous system in which symptoms and disability progression vary significantly among patients. Teri-REAL was a prospective, real-world observational study that examined quality-of-life (QoL) and trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bencsik, Krisztina, Dobos, Enikő, Jobbágy, Zita, Birkás, Adrienne Jóri, Kovács, Krisztina, Sátori, Mária, Lencsés, Gyula, Bartok, Gabor, Losonczi, Erika, Vécsei, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145304/ https://www.ncbi.nlm.nih.gov/pubmed/35631424 http://dx.doi.org/10.3390/ph15050598

Ejemplares similares

Do Hungarian multiple sclerosis care units fulfil international criteria?
por: Kokas, Zsófia, et al.
Publicado: (2022)

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
por: Zhang, Yao, et al.
Publicado: (2022)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
por: Meca-Lallana, José E., et al.
Publicado: (2023)

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2022)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
por: Biernacki, Tamás, et al.
Publicado: (2020)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy—Kynurenines Are Important Players
por: Sandi, Dániel, et al.
Publicado: (2021)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
por: Greene, Nupur, et al.
Publicado: (2022)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

The validity of the diabetes self-management questionnaire (DSMQ) in Hungarian patients with type 2 diabetes
por: Vincze, Agnes, et al.
Publicado: (2020)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease
por: Gal, Aniko, et al.
Publicado: (2021)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Orbán, Ilonka, et al.
Publicado: (2018)

Proteomics in Multiple Sclerosis: The Perspective of the Clinician
por: Sandi, Dániel, et al.
Publicado: (2022)

Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
por: Kieseier, Bernd C., et al.
Publicado: (2014)

Tolerability and discontinuation rates in teriflunomide-treated patients: A real-world clinical experience
por: Alnajashi, Hind A., et al.
Publicado: (2018)

The effects of dissection-room experiences and related coping strategies among Hungarian medical students
por: Sándor, Imola, et al.
Publicado: (2015)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
por: Landete, Lamberto, et al.
Publicado: (2021)

Prevalence of reflux-related symptoms in South-Hungarian blood donor volunteers
por: Helle, Krisztina, et al.
Publicado: (2022)

Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society
por: Rajda, Cecilia, et al.
Publicado: (2023)

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
por: Varga, Gergely, et al.
Publicado: (2021)

Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report
por: D’Aleo, Giangaetano, et al.
Publicado: (2020)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
por: Hardy, Todd A, et al.
Publicado: (2022)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

Clinical and health policy experiences with HPV prevalence within the Hungarian organized cervical cancer screening program
por: Vajda, Réka, et al.
Publicado: (2018)

The prevalence of ADH1B and OPRM1 alleles predisposing for alcohol consumption are increased in the Hungarian psoriasis population
por: Szentkereszty-Kovács, Zita, et al.
Publicado: (2019)

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
por: Kallmann, Boris A., et al.
Publicado: (2019)

Structural and functional characterization of IdiA/FutA (Tery_3377), an iron-binding protein from the ocean diazotroph Trichodesmium erythraeum
por: Polyviou, Despo, et al.
Publicado: (2018)

EHMTI-0127. Three faces of pain-herpes zooster ophthalmicus
por: Birkas, A Jori
Publicado: (2014)

Delineating the genetic heterogeneity of OCA in Hungarian patients
por: Fábos, Beáta, et al.
Publicado: (2017)

Contributing factors to health‐related quality of life in multiple sclerosis
por: Biernacki, Tamás, et al.
Publicado: (2019)

Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
por: Hendin Travis, Lori, et al.
Publicado: (2018)

Comparison of typical Thai and Hungarian personality profiles using the Zuckerman–Kuhlman–Aluja Personality Questionnaire
por: Kövi, Zsuzsanna, et al.
Publicado: (2023)

Reducing the Nighttime Fears of Young Children Through a Brief Parent-Delivered Treatment—Effectiveness of the Hungarian Version of Uncle Lightfoot
por: Kopcsó, Krisztina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fbt7n4mmgihanckg62li8fthpo